AnaptysBio Inc - ESG Rating & Company Profile powered by AI
The article includes a Q&A section about AnaptysBio Inc. The page contains a free Environmental, Social and Governance assessment covering AnaptysBio Inc. If you work at AnaptysBio Inc and you would like to licence your ESG aseessment, please get in touch.
AnaptysBio Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.3; made up of an environmental score of 2.0, social score of 1.6 and governance score of 3.2.
2.3
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1512 | Sol Gel Technologies Ltd | 2.4 | Medium |
| 1512 | Windtree Therapeutics Inc | 2.4 | Medium |
| 1529 | AnaptysBio Inc | 2.3 | Medium |
| 1529 | ANI Pharmaceuticals Inc | 2.3 | Medium |
| 1529 | Aarti Drugs Ltd | 2.3 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does AnaptysBio Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes AnaptysBio Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes AnaptysBio Inc report the average age of the workforce?
Sign up for free to unlockDoes AnaptysBio Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes AnaptysBio Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes AnaptysBio Inc disclose cybersecurity risks?
Sign up for free to unlockDoes AnaptysBio Inc offer flexible work?
Sign up for free to unlockDoes AnaptysBio Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes AnaptysBio Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes AnaptysBio Inc conduct supply chain audits?
Sign up for free to unlockDoes AnaptysBio Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes AnaptysBio Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes AnaptysBio Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes AnaptysBio Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes AnaptysBio Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes AnaptysBio Inc disclose water use targets?
Sign up for free to unlockDoes AnaptysBio Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid AnaptysBio Inc have a product recall in the last two years?
Sign up for free to unlockDoes AnaptysBio Inc disclose incidents of discrimination?
Sign up for free to unlockDoes AnaptysBio Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas AnaptysBio Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes AnaptysBio Inc disclose parental leave metrics?
Sign up for free to unlockDoes AnaptysBio Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes AnaptysBio Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes AnaptysBio Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes AnaptysBio Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes AnaptysBio Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes AnaptysBio Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs AnaptysBio Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes AnaptysBio Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes AnaptysBio Inc disclose its waste policy?
Sign up for free to unlockDoes AnaptysBio Inc report according to TCFD requirements?
Sign up for free to unlockDoes AnaptysBio Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes AnaptysBio Inc disclose energy use targets?
Sign up for free to unlockDoes AnaptysBio Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes AnaptysBio Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for AnaptysBio Inc
These potential risks are based on the size, segment and geographies of the company.
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.